Alex Sticchi, interventional cardiologist, interviews Rebecca Hahn, Interventional Echocardiographer about a recent State of the Art article about transcatheter treatment for tricuspid valve disease published in EuroIntervention.
They discuss the importance of starting with the classification of anatomy and that of secondary TR and why recognising disease severity is a challenge, as well as identifying how clinical cardiolologists can recognise severity via TTE as first-level before a multimodality imaging approach. RV assessment is another essential parameter in the evaluation of patients - is TAPSE/SPAP currently the most trustable value for determining it? And could we hypothesize to extend it to other interventions as a prognostic predictor? Device selection is a very interesting theme, and preprocedural CCT is mandatory besides 3D TEE. In conclusion, Rebecca Hahn shares her perspective about patient eligibility in Tricuspid intervention, repair and replacement in the future!
Chapters:
00:00 - Introduction
01:38 - 1st question - The manuscript started with the Anatomy classification proposal previously published by Hahn et al. in JACC: Cardiovascular Imaging in July. Why is the tricuspid valve the only valve with a new classification proposal? And why is it so important to start from here?
04:02 - 2nd question - What is new in the proposed integrated classification of Secondary TR?
07:04 - 3rd question - What advice can we share with clinical cardiologists to recognize the disease severity via TTE as first-level before a multimodality imaging approach?
09:51 - 4th question - Is TAPSE/SPAP currently the most trustable value for determining it? And could we hypothesize to extend it to other interventions as a prognostic predictor?
14:01 - 5th question - What is your perspective about patient eligibility in Tricuspid intervention, repair and replacement in the future? What are the possible solutions?
Read this State of the Art article here
[ Ссылка ]
EuroIntervention 2021;17:791-808. DOI: 10.4244/EIJ-D-21-00695
View more content from the PCR Tricuspid Focus Group here
[ Ссылка ]
#PCRTricuspid #TreatTR #FixTR
